Multicentre, randomised, open label, non-inferiority active-controlled trial to evaluate the efficacy and safety of deferiprone compared to deferasirox in paediatric patients aged from 1 month to less than 18 years of age affected by transfusion-dependent haemoglobinopathies.
Phase of Trial: Phase III
Latest Information Update: 16 Jun 2019
Price : $35 *
At a glance
- Drugs Deferiprone (Primary) ; Deferasirox
- Indications Haemosiderosis
- Focus Therapeutic Use
- Acronyms DEEP-2
- 31 Aug 2018 Biomarkers information updated
- 19 Oct 2017 Status changed from active, no longer recruiting to completed.
- 21 Mar 2017 Planned End Date changed from 1 Apr 2017 to 1 Aug 2017.